Gadobutrol is a gadolinium-based contrast agent used in magnetic resonance imaging (MRI) to enhance the clarity of internal body structures, particularly the brain, spine, and blood vessels. It belongs to a class of compounds built around the paramagnetic metal gadolinium, which improves image contrast by altering local magnetic fields during scanning. Developed by Bayer AG, gadobutrol was introduced in the late 20th century as a non-ionic, macrocyclic contrast agent designed for higher stability and lower risk of releasing free gadolinium ions compared to earlier linear agents. It gained regulatory approvals in Europe in the 1990s and later in other regions, including the United States in 2011 under the brand name Gadavist. Over time, gadobutrol has become widely used in clinical practice due to its high concentration, strong imaging performance, and improved safety profile, especially in reducing risks such as nephrogenic systemic fibrosis associated with some older gadolinium-based contrast agents.
BRAND NAMES
Gadobutrol is a gadolinium-based contrast agent (GBCA) used in MRI imaging and is marketed by Bayer under the brand names Gadavist (in the United States and Canada) and Gadovist (in Europe and other regions). It is a 1.0 M, macrocyclic, non-ionic contrast agent that helps enhance the visualization of lesions and blood vessels in central nervous system, body, and cardiac imaging.
MECHANISM OF ACTION
Gadobutrol (marketed as Gadovist) is a non-ionic, macrocyclic, paramagnetic gadolinium-based contrast agent (GBCA) used in MRI to improve tissue visualization. It acts by shortening the spin-lattice (T₁) and spin-spin (T₂) relaxation times of nearby water protons, which results in increased signal intensity, making structures appear brighter on T₁-weighted images.
PHARMACOKINETICS
Distribution
After intravenous administration, gadobutrol distributes within the extracellular space. Gadobutrol does not exhibit any significant binding to plasma proteins. After administration of a gadolinium-based contrast agent (GBCA), gadolinium can persist for months or even years in tissues such as the brain, bones, skin, and other organs.
Metabolism
Not metabolized; remains chemically unchanged due to its stable macrocyclic structure.
Elimination
The average elimination half-life (t½) of gadobutrol is approximately 1.8 hours.
PHARMACODYNAMICS
Gadobutrol is a second-generation, extracellular, non-ionic, macrocyclic gadolinium-based contrast agent (GBCA) used in magnetic resonance imaging (MRI) and magnetic resonance angiography (MRA). It enhances imaging by shortening the T₁ and T₂ relaxation times of water protons, resulting in increased signal intensity and brighter appearance on T₁-weighted images.
ADMINISTRATION
Gadobutrol (marketed as Gadavist / Gadovist) is a 1.0 molar gadolinium-based contrast agent used in MRI examinations. It is administered through intravenous injection into the venous system, typically followed by a flush of 0.9% sodium chloride. This agent is suitable for use in adults, children, and full-term neonates to improve contrast in imaging studies.
DOSAGE AND STRENGTH
The dosage and strength of Gadobutrol are defined by its formulation as a 1.0 molar (1 mmol/mL) solution. It is administered as a single intravenous bolus injection, with a typical recommended dose of 0.1 mmol per kilogram of body weight. This dosing approach is generally applicable to adults, pediatric patients, and term neonates, and is often followed by a saline flush to ensure complete administration of the contrast agent.
DRUG INTERACTIONS
Gadobutrol (marketed as Gadavist) is known to have several moderate drug interactions, mainly with medications that influence kidney function or blood pressure, such as Betaxolol. It is generally considered safe, with no major contraindications identified in studies.
FOOD INTERACTIONS
Gadobutrol (Gadavist) has no known direct interactions with food. Because it is administered intravenously for MRI procedures, gadobutrol can be given regardless of food intake. However, patients should always inform their healthcare provider about any allergies, especially food or dye allergies, prior to receiving the injection.
CONTRAINDICATIONS
Gadobutrol (marketed as Gadavist / Gadovist) is contraindicated in individuals with a known history of severe hypersensitivity reactions to gadobutrol. It should be used with great caution, or avoided when possible, in patients with chronic severe kidney disease or acute kidney injury because of the potential risk of developing nephrogenic systemic fibrosis (NSF).
SIDE EFFECTS
Headache
Nausea
Dizziness
Altered taste (dysgeusia)
Injection site reactions (pain, warmth)
OVER DOSE
Gadobutrol (commonly sold as Gadavist or Gadovist) is a macrocyclic, non-ionic gadolinium-based contrast agent (GBCA) known for its strong safety profile. In clinical use, no evidence of acute toxicity or intoxication has been observed, even when doses exceed the recommended levels.
TOXICITY
Gadobutrol (Gadavist) is a macrocyclic, non-ionic gadolinium-based contrast agent (GBCA) that is generally regarded as safe, with a low reported rate of adverse events of about 3.4–4.2%. The main safety concern is the development of Nephrogenic Systemic Fibrosis in patients with severe renal impairment, along with rare cases of allergic reactions.
